R

Ultragenyx Pharmaceutical
D

RARE

47.085
USD
1.11
(2.40%)
Market Open
Volume
7,070
EPS
-6
Div Yield
-
P/E
-7
Market Cap
4,348,029,859
OverviewSignalsIdeasNews
Related Instruments
    B
    BLUE
    -0.04270
    (-11.74%)
    0.32090 USD
    C
    CLRB
    -0.14500
    (-7.23%)
    1.86000 USD
    C
    CRIS
    -0.04000
    (-1.00%)
    3.96000 USD
    F
    FATE
    -0.04500
    (-2.17%)
    2.02500 USD
    K
    KRYS
    -6.865
    (-3.87%)
    170.590 USD
    M
    MGTX
    -0.18000
    (-2.71%)
    6.47000 USD
    S
    SRPT
    -4.470
    (-4.10%)
    104.600 USD
    V
    VCEL
    -0.240
    (-0.46%)
    52.510 USD
    V
    VCYT
    -1.085
    (-2.93%)
    35.955 USD
    More
News

Title: Ultragenyx Pharmaceutical

Sector: Healthcare
Industry: Biotechnology
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.